#403 ‒ Peptides: separating scientific promise from marketing hype
Peter Attia provides a framework for evaluating peptides, distinguishing scientific promise from misinformation. He examines the evidence for popular peptides like BPC-157 and CJC-1295, discusses the role of FDA approval and gray market risks, and emphasizes evidence-based decision-making.
Deep Dive Analysis
14 Topic Outline
Introduction to Peptides and Misinformation
Defining Peptides and the Need for Individual Evaluation
Five-Question Framework for Evaluating Any Drug
Three-Tier System for Classifying Peptide Evidence
Case Study: Evaluating BPC-157 with the Framework
The Problem with BPC-157's Expanding Claims
Evaluating Peptides with Plausible Biology: CJC-1295
Addressing Testimonials and the Placebo Effect
The Role of FDA Approval in Peptide Evaluation
Limitations of Doctor Prescriptions, Compounding, and Third-Party Testing
Gray Market Peptides vs. Approved Drug Products
Debunking the 'Natural Peptides Can't Be Patented' Claim
Key Takeaways on the Current Peptide Landscape
The Importance of Falsifiability in Scientific Claims
6 Key Concepts
Peptide
A short chain of amino acids, a chemical description that does not inherently indicate safety, effectiveness, or scientific plausibility. Many commercially available peptides are synthetic modifications of natural molecules.
Mechanism of Action
The specific molecular target and downstream changes a drug induces, explaining how it plausibly produces a clinical effect. A clear mechanism makes a claim falsifiable and helps identify potential failure modes.
Pharmacokinetics (PK)
Describes how a drug moves through the body, including how much reaches circulation, how long it stays active, and its metabolism and excretion. Understanding PK is crucial for safe and effective dosing.
Regression to the Mean
A statistical phenomenon where extreme measurements tend to be followed by measurements closer to the average. In health, this means people often start treatments when feeling their worst, and natural improvement is often mistakenly attributed to the intervention.
Placebo Effect
A genuine physiological or psychological effect produced by a treatment that is not due to its specific active components. It is influenced by expectation, ritual, context, and narrative, and can significantly impact subjective outcomes like pain or perceived energy.
Falsifiability
The principle that a scientific hypothesis must be capable of being proven wrong by observation or experiment. Claims that cannot be disproven, regardless of outcome, are not scientific and cannot be corrected by evidence.
8 Questions Answered
Peptides are short chains of amino acids, a chemical description that provides no inherent information about their safety or effectiveness, with many commercially available versions being synthetic modifications.
You should evaluate peptides using a five-question framework focusing on their mechanism of action, human clinical evidence, understanding of safety/dosing, risk-benefit justification, and comparison to better-characterized alternatives.
Peptides with claims that continuously grow across many therapeutic areas without rigorous evidence for initial indications are often a sign of marketing hype rather than legitimate drug development, which typically narrows uncertainty over time.
No, testimonials only describe what happened after someone took a drug and cannot account for what would have happened without it, nor do they control for factors like regression to the mean, co-interventions, or the powerful placebo effect.
The placebo effect can be genuinely powerful for subjective outcomes like pain or perceived energy, especially when a peptide is presented with a compelling narrative, high cost, and ritualistic administration like injection.
FDA approval signifies that a drug has undergone formal development, providing crucial information on its defined benefits, study dose, safety profile, manufacturing standards, and post-market surveillance, which is vital for informed decision-making.
While these might reduce some risks like improper administration or purity issues for a specific batch, they do not create the missing clinical evidence, manufacturing controls, or long-term monitoring required for a defensible risk-benefit assessment of an unapproved peptide.
Pharmaceutical companies can and do patent modified natural molecules, and their lack of development for many gray market peptides often indicates these compounds were abandoned due to inadequate efficacy, safety concerns, or poor commercial prospects, rather than an inability to patent.
9 Actionable Insights
1. Evaluate Peptides Systematically
Use a five-question framework to assess any peptide: viable mechanism, human benefit evidence, safety/dosing/PK understanding, benefit-risk justification, and existence of better-characterized alternatives. This removes personal bias and applies to any drug.
2. Be Wary of Unfalsifiable Claims
If no observation can prove a peptide claim wrong, and disappointing outcomes are always explained away by external factors, it’s likely marketing, not science. Prioritize claims that are testable and correctable by evidence.
3. Prioritize FDA-Approved Products
Opt for drugs that have completed formal FDA development, as this provides crucial information on defined benefits, study doses, safety profiles, and manufacturing standards, enabling evidence-informed risk-benefit decisions.
4. Understand Peptide Evidence Tiers
Classify peptides into three buckets: scientifically unsupported (avoid), biologically plausible but no human evidence (temper enthusiasm), and scientifically legitimate (use well-characterized versions, understand specific evidence). This guides appropriate use and skepticism.
5. Distinguish Molecule from Product
Recognize that a pharmaceutical is more than just a molecular structure; it’s a specific product manufactured under stringent processes with specific formulation and characteristics. Evidence for an approved drug does not automatically extend to gray-market versions with the same amino acid sequence.
6. Question Broad, Expanding Claims
Be skeptical of peptides whose purported benefits expand across many therapeutic areas without rigorous evidence for initial claims. Legitimate drug development narrows uncertainty and earns new indications over time, while bad science expands claims.
7. Do Not Over-rely on Testimonials
Understand that personal anecdotes only describe what happened after someone took a drug, not what would have happened without it. They cannot account for regression to the mean, co-interventions, or the powerful placebo effect, which are all addressed by controlled trials.
8. Recognize the Power of Placebo
Be aware that perceived benefits from peptides can be significantly shaped by expectation, behavioral changes, and the ritual of treatment, especially for subjective outcomes like pain or energy. Controlled human trials are essential to separate the drug’s effect from its surrounding narrative.
9. Be Skeptical of ‘Natural’ Claims
Understand that most peptides used are synthetic modifications, and pharmaceutical companies can and do patent modified natural molecules. The absence of pharma development for a peptide often indicates it was abandoned due to inadequate efficacy, safety, or commercial prospects, not lack of patentability.
9 Key Quotes
Hope has become a product. It's being sold by attaching extraordinary claims to molecules that in many cases have never earned such claims.
Peter Atiyah
The word tells you almost nothing about whether a molecule is safe, effective, or even scientifically plausible. It's a chemical description, not a mark of quality.
Peter Atiyah
A drug isn't simply evidence-based. It's evidence-based for a particular dose, route of administration, patient population, indication, and clinical endpoint.
Peter Atiyah
This is basically the scientific equivalent of trust me, bro.
Peter Atiyah
Legitimate drug development narrows uncertainty over time. Bad science or no science expands its claims instead.
Peter Atiyah
The issue is whether that activity translates into a meaningful human benefit at a dose we understand with risks worth accepting.
Peter Atiyah
The RCT is there to tell you how much additional benefit belongs to the drug.
Peter Atiyah
The gray market isn't an alternative to pharma. It's the salvage yard for the drugs pharma tested and walked away from.
Peter Atiyah
A hypothesis has to be falsifiable or it can't be corrected by evidence.
Peter Atiyah
2 Protocols
Framework for Evaluating Peptides and Other Drugs
Peter Atiyah- Is there a viable mechanism of action?
- Do we have evidence of a meaningful benefit in humans?
- Do we understand safety, dosing, and pharmacokinetics?
- Does the likely benefit justify the risk for this person?
- Is there a better characterized way to get the same result?
Three-Tier System for Classifying Peptide Evidence
Peter Atiyah- **Bucket 1 (Scientifically Unsupported):** No validated mechanism, little/no credible human evidence, claims drift. Conclusion: Not enough scientific foundation to justify use.
- **Bucket 2 (Biologically Plausible, No Human Evidence):** Credible mechanism, worked in animal studies, but no human outcome improvement. Development often stalled/halted. Conclusion: Biology may be real, but clinical benefit not demonstrated, or potential harm too high.
- **Bucket 3 (Scientifically Legitimate Molecules):** Strongest scientific footing, likely biologically meaningful effect. Evidence is specific (dose, route, population, indication, endpoint). Conclusion: Use product with strongest characterization and oversight, understand risks of less characterized versions.